These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 38203596)

  • 1. PIM Kinase Inhibition Attenuates the Malignant Progression of Metastatic Hepatoblastoma.
    Julson JR; Quinn CH; Butey S; Erwin MH; Marayati R; Nazam N; Stewart JE; Beierle EA
    Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PIM kinases mediate resistance to cisplatin chemotherapy in hepatoblastoma.
    Marayati R; Stafman LL; Williams AP; Bownes LV; Quinn CH; Aye JM; Stewart JE; Yoon KJ; Anderson JC; Willey CD; Beierle EA
    Sci Rep; 2021 Mar; 11(1):5984. PubMed ID: 33727604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PIM Kinase Inhibition Sensitizes Neuroblastoma to Doxorubicin.
    Julson JR; Quinn CH; Nazam N; Bownes LV; Stewart JE; Beierle EA
    J Pediatr Surg; 2024 Jul; 59(7):1334-1341. PubMed ID: 38570263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting PIM kinase as a therapeutic strategy in human hepatoblastoma.
    Stafman LL; Mruthyunjayappa S; Waters AM; Garner EF; Aye JM; Stewart JE; Yoon KJ; Whelan K; Mroczek-Musulman E; Beierle EA
    Oncotarget; 2018 Apr; 9(32):22665-22679. PubMed ID: 29854306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pan-Pim Kinase Inhibitor AZD1208 Suppresses Tumor Growth and Synergistically Interacts with Akt Inhibition in Gastric Cancer Cells.
    Lee M; Lee KH; Min A; Kim J; Kim S; Jang H; Lim JM; Kim SH; Ha DH; Jeong WJ; Suh KJ; Yang YW; Kim TY; Oh DY; Bang YJ; Im SA
    Cancer Res Treat; 2019 Apr; 51(2):451-463. PubMed ID: 29879757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AZD1208, a Pan-Pim Kinase Inhibitor, Has Anti-Growth Effect on 93T449 Human Liposarcoma Cells via Control of the Expression and Phosphorylation of Pim-3, mTOR, 4EBP-1, S6, STAT-3 and AMPK.
    Yadav AK; Kumar V; Bailey DB; Jang BC
    Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30654529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protein profiling identifies mTOR pathway modulation and cytostatic effects of Pim kinase inhibitor, AZD1208, in acute myeloid leukemia.
    Chen LS; Yang JY; Liang H; Cortes JE; Gandhi V
    Leuk Lymphoma; 2016 Dec; 57(12):2863-2873. PubMed ID: 27054578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PIM447 inhibits oncogenesis and potentiates cisplatin effects in hepatoblastoma.
    Wadhwani N; Markert HR; Marayati R; Bownes LV; Quinn CH; Aye JM; Stewart JE; Yoon KJ; Beierle EA
    J Pediatr Surg; 2021 Jun; 56(6):1157-1164. PubMed ID: 33762119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia.
    Keeton EK; McEachern K; Dillman KS; Palakurthi S; Cao Y; Grondine MR; Kaur S; Wang S; Chen Y; Wu A; Shen M; Gibbons FD; Lamb ML; Zheng X; Stone RM; Deangelo DJ; Platanias LC; Dakin LA; Chen H; Lyne PD; Huszar D
    Blood; 2014 Feb; 123(6):905-13. PubMed ID: 24363397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The novel combination of dual mTOR inhibitor AZD2014 and pan-PIM inhibitor AZD1208 inhibits growth in acute myeloid leukemia via HSF pathway suppression.
    Harada M; Benito J; Yamamoto S; Kaur S; Arslan D; Ramirez S; Jacamo R; Platanias L; Matsushita H; Fujimura T; Kazuno S; Kojima K; Tabe Y; Konopleva M
    Oncotarget; 2015 Nov; 6(35):37930-47. PubMed ID: 26473447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting PIM Kinases Affects Maintenance of CD133 Tumor Cell Population in Hepatoblastoma.
    Stafman LL; Williams AP; Garner EF; Aye JM; Stewart JE; Yoon KJ; Whelan K; Beierle EA
    Transl Oncol; 2019 Feb; 12(2):200-208. PubMed ID: 30412911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PIM kinase inhibitor AZD1208 for treatment of MYC-driven prostate cancer.
    Kirschner AN; Wang J; van der Meer R; Anderson PD; Franco-Coronel OE; Kushner MH; Everett JH; Hameed O; Keeton EK; Ahdesmaki M; Grosskurth SE; Huszar D; Abdulkadir SA
    J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25505253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells.
    Mazzacurati L; Lambert QT; Pradhan A; Griner LN; Huszar D; Reuther GW
    Oncotarget; 2015 Nov; 6(37):40141-57. PubMed ID: 26472029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PIM kinase inhibitor AZD1208 in conjunction with Th1 cytokines potentiate death of breast cancer cellsin vitrowhile also maximizing suppression of tumor growthin vivo when combined with immunotherapy.
    Anwar A; Lepore C; Czerniecki BJ; Koski GK; Showalter LE
    Cell Immunol; 2024; 397-398():104805. PubMed ID: 38244265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting PIM Kinase with PD1 Inhibition Improves Immunotherapeutic Antitumor T-cell Response.
    Chatterjee S; Chakraborty P; Daenthanasanmak A; Iamsawat S; Andrejeva G; Luevano LA; Wolf M; Baliga U; Krieg C; Beeson CC; Mehrotra M; Hill EG; Rathmell JC; Yu XZ; Kraft AS; Mehrotra S
    Clin Cancer Res; 2019 Feb; 25(3):1036-1049. PubMed ID: 30327305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New Mechanistic Insight on the PIM-1 Kinase Inhibitor AZD1208 Using Multidrug Resistant Human Erythroleukemia Cell Lines and Molecular Docking Simulations.
    Marques MB; González-Durruthy M; da Silva Nornberg BF; Oliveira BR; Almeida DV; de Souza Votto AP; Marins LF
    Curr Top Med Chem; 2019; 19(11):914-926. PubMed ID: 31072293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PIM3 kinase promotes tumor metastasis in hepatoblastoma by upregulating cell surface expression of chemokine receptor cxcr4.
    Marayati R; Julson J; Bownes LV; Quinn CH; Stafman LL; Beierle AM; Markert HR; Hutchins SC; Stewart JE; Crossman DK; Hjelmeland AB; Mroczek-Musulman E; Beierle EA
    Clin Exp Metastasis; 2022 Dec; 39(6):899-912. PubMed ID: 36315303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AZD1208, a pan-Pim kinase inhibitor, inhibits adipogenesis and induces lipolysis in 3T3-L1 adipocytes.
    Park YK; Obiang-Obounou BW; Lee KB; Choi JS; Jang BC
    J Cell Mol Med; 2018 Apr; 22(4):2488-2497. PubMed ID: 29441719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting of glioblastoma cell lines and glioma stem cells by combined PIM kinase and PI3K-p110α inhibition.
    Iqbal A; Eckerdt F; Bell J; Nakano I; Giles FJ; Cheng SY; Lulla RR; Goldman S; Platanias LC
    Oncotarget; 2016 May; 7(22):33192-201. PubMed ID: 27120806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pim kinase inhibition sensitizes FLT3-ITD acute myeloid leukemia cells to topoisomerase 2 inhibitors through increased DNA damage and oxidative stress.
    Doshi KA; Trotta R; Natarajan K; Rassool FV; Tron AE; Huszar D; Perrotti D; Baer MR
    Oncotarget; 2016 Jul; 7(30):48280-48295. PubMed ID: 27374090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.